Cantor Fitzgerald restated an overweight rating for MoonLake Immunotherapeutics, which trades on Nasdaq, with data provided by MarketBeat.
1 report, 1 independent
Updated Sun 00:00
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald restated an overweight rating for MoonLake Immunotherapeutics, which trades on Nasdaq, with data provided by MarketBeat.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Cantor Fitzgerald
American financial services company
-
MarketBeat
American personal finance blog
- MarketBeat has provided analyst ratings and targets for two large-cap materials companies: Vulcan Materials Company and Heidelberg Materials.
- Citigroup reiterated a market perform rating, Bank of America restated an underperform rating, and Raymond James Financial started coverage for Omega Healthcare Investors, Inc.
-
Nasdaq
American fully electronic stock exchange
Related events
- MarketBeat reported the stock's average rating while Citigroup reiterated a buy rating and Cantor Fitzgerald restated an overweight rating for Beta Technologies.
- MarketBeat provided consensus ratings while Cantor Fitzgerald and Jefferies Financial Group issued rating updates for Primoris Services Corporation.
- Cantor Fitzgerald reiterated an overweight rating for Sterling Infrastructure on November 1, 2026.
- Citigroup and Cantor Fitzgerald issued rating updates, while disclosures were required by the SEC.
- Cantor Fitzgerald reiterated an overweight rating for IREN on November 3, 2026.